Rimsa: Teva and Rimsa Settle Contested $2.3-Billion Acquisition Deal Out of Court
Teva acquired the Mexican plant in 2016 but shut it down immediately, citing discrepancies between Rimsa's regulatory filing and the actual assets, and filed a suit against the former owners
Read full article »
CEO
Luis Jorge Perez Juarez
Rimsa Laboratories designs, develops, manufactures and markets generic drug products for the treatment of musculoskeletal.
Read more